COSMOS Pharmaceutical Corporation

TSE:3349 Stock Report

Market Cap: JP¥743.1b

COSMOS Pharmaceutical Future Growth

Future criteria checks 2/6

COSMOS Pharmaceutical is forecast to grow earnings and revenue by 5.1% and 6.3% per annum respectively. EPS is expected to grow by 5.1% per annum. Return on equity is forecast to be 10.8% in 3 years.

Key information

5.1%

Earnings growth rate

5.1%

EPS growth rate

Consumer Retailing earnings growth12.5%
Revenue growth rate6.3%
Future return on equity10.8%
Analyst coverage

Good

Last updated28 Apr 2025

Recent future growth updates

COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 16
COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Jan 17
COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 16
COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Should You Be Adding COSMOS Pharmaceutical (TSE:3349) To Your Watchlist Today?

Mar 27
Should You Be Adding COSMOS Pharmaceutical (TSE:3349) To Your Watchlist Today?

COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

Mar 11
COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

COSMOS Pharmaceutical Corporation's (TSE:3349) Business Is Yet to Catch Up With Its Share Price

Jan 31
COSMOS Pharmaceutical Corporation's (TSE:3349) Business Is Yet to Catch Up With Its Share Price

COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Jan 17
COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Here's Why COSMOS Pharmaceutical (TSE:3349) Can Manage Its Debt Responsibly

Dec 25
Here's Why COSMOS Pharmaceutical (TSE:3349) Can Manage Its Debt Responsibly

COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

Nov 18
COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Sep 26
We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

Aug 17
An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Aug 01
COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

Jun 28
Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Jun 10
We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Earnings and Revenue Growth Forecasts

TSE:3349 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
5/31/20271,165,99433,7367,133N/A11
5/31/20261,085,89031,9234,955N/A12
5/31/20251,014,87130,171-1,893N/A12
2/28/20251,001,94629,440N/AN/AN/A
11/30/2024994,49527,2953,53553,314N/A
8/31/2024985,17726,089N/AN/AN/A
5/31/2024964,98924,454-63555,175N/A
2/29/2024936,70624,871N/AN/AN/A
11/30/2023900,11124,08568154,534N/A
8/31/2023863,22823,824N/AN/AN/A
5/31/2023827,69723,7977,79854,434N/A
2/28/2023802,83122,983N/AN/AN/A
11/30/2022788,29223,209-3,65541,973N/A
8/31/2022772,12723,393N/AN/AN/A
5/31/2022755,41423,155-11,30332,194N/A
2/28/2022743,61222,030N/AN/AN/A
11/30/2021733,38725,329-535,596N/A
8/31/2021726,67225,909N/AN/AN/A
5/31/2021726,42427,1561,81127,875N/A
2/28/2021733,22328,777N/AN/AN/A
11/30/2020723,30925,73628,88250,935N/A
8/31/2020709,06423,876N/AN/AN/A
5/31/2020684,40321,43539,51365,461N/A
2/29/2020653,52720,217N/AN/AN/A
11/30/2019638,03418,95110,65338,209N/A
8/31/2019622,10319,349N/AN/AN/A
5/31/2019611,13719,1855,33934,379N/A
2/28/2019597,71518,966N/AN/AN/A
11/30/2018585,53618,857N/A30,947N/A
8/31/2018572,80717,880N/AN/AN/A
5/31/2018557,99917,633N/A32,586N/A
2/28/2018542,93617,510N/AN/AN/A
11/30/2017526,52317,313N/A35,488N/A
8/31/2017514,88018,239N/AN/AN/A
5/31/2017502,73218,215N/A36,938N/A
2/28/2017490,03715,812N/AN/AN/A
11/30/2016477,73914,981N/A34,300N/A
8/31/2016463,51713,679N/AN/AN/A
5/31/2016447,27312,435N/A30,986N/A
2/29/2016433,32812,738N/AN/AN/A
11/30/2015423,81712,474N/A22,426N/A
8/31/2015414,04612,350N/AN/AN/A
5/31/2015408,46611,694N/A19,454N/A
2/28/2015402,69010,671N/AN/AN/A
11/30/2014392,52710,286N/A26,260N/A
8/31/2014382,82310,193N/AN/AN/A
5/31/2014371,82510,600N/A25,962N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3349's forecast earnings growth (5.1% per year) is above the savings rate (0.4%).

Earnings vs Market: 3349's earnings (5.1% per year) are forecast to grow slower than the JP market (7.6% per year).

High Growth Earnings: 3349's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3349's revenue (6.3% per year) is forecast to grow faster than the JP market (4.1% per year).

High Growth Revenue: 3349's revenue (6.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 3349's Return on Equity is forecast to be low in 3 years time (10.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 11:58
End of Day Share Price 2025/05/08 00:00
Earnings2025/02/28
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

COSMOS Pharmaceutical Corporation is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arashi NishizawaBofA Global Research
Mitsuru TakayanagiCitigroup Inc
Jun KawaharaDaiwa Securities Co. Ltd.